← Leaderboards
William Schary
7 Hills Pharma, Llc
$1,136,559
Attributed
$3,880,101
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2023–24$2M$1.5M$1M$500K$0
'23
'24
Funding mix
By agency
NIH$3,880,101 · 2
By mechanism
R44$3,880,101 · 2
Top collaborators
- Upendra Marathi4 shared
- Siddhartha De2 shared
- Lionel David Lewis2 shared
- Michael Schotsaert2 shared
Others in their field
Other Rising Stars on “T-Cell Activation”
- Lisa Wagar · University Of California-Irvine$7,863,777
- Magnus Adrian Gero Hoffmann · California Institute Of Technology$5,819,250
- Kenneth Schultz · Trethera Corporation$5,264,077
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
- Dmitriy Zamarin · Sloan-Kettering Inst Can Research$3,427,557
- Steven Bradfute · Albert Einstein College Of Medicine$3,407,726
Research focus
T-Cell ActivationEffectivenessFoundationsSafetyRecommendationFutureDoseFirst-In-HumanIntegrinsResponseT-LymphocyteT Cell ResponseOralIntegrin Alpha4beta1Antigen PresentationClinical ResearchDrug KineticsAnti-Ctla4Antibody ResponseAgingAnimal ModelBiological AvailabilityAnaplastic Lymphoma KinaseAge Related
Grant awards (4)
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors$999,200
R44 · FY2024 · CA
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$953,477
R44 · FY2024 · AI
7HP349, an Integrin Activator to Treat Patients With anti-PD-1 Resistant Solid Tumors$999,200
R44 · FY2023 · CA
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccination$928,224
R44 · FY2023 · AI